BeOne Medicines
ONC
#652
Rank
HK$278.15 B
Marketcap
HK$2,514
Share price
-2.56%
Change (1 day)
57.13%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeOne Medicines (ONC) - Total debt

Total debt on the balance sheet as of September 2025 : HK$7.94 Billion

According to BeOne Medicines's latest financial reports the company's total debt is HK$7.94 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeOne Medicines - Total debt on balance sheet (from 2014 to 2025)

Total debt by year

Year Total debt Change
2024-12-31HK$8.38 B15.4%
2023-12-31HK$7.26 B55.83%
2022-12-31HK$4.66 B-13.93%
2021-12-31HK$5.41 B24.33%
2020-12-31HK$4.35 B101.69%
2019-12-31HK$2.15 B39.03%
2018-12-31HK$1.55 B20.73%
2017-12-31HK$1.28 B860.17%
2016-12-31HK$0.13 B-16.81%
2015-12-31HK$0.16 B50.1%
2014-12-31HK$0.10 B-49.42%
2013-12-31HK$0.21 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Onconova Therapeutics
ONTX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$3.07 B-61.23%๐Ÿ‡บ๐Ÿ‡ธ USA